Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine

This article was originally published in The Pink Sheet Daily

Executive Summary

Clovis takes over work on Clavis's pancreatic cancer drug and will develop a companion test to target patients who fare poorly on Lilly's current standard of care.
Advertisement

Related Content

Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
Clovis Oncology Seeks $149.5 Million IPO
Clovis Oncology Seeks $149.5 Million IPO
Clovis And Clavis' Gemcitabine Derivative Partnership Goes From Regional To Worldwide
Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market
Deals Of The Week: Clovis/Clavis; Novartis/Incyte; Jubilant/UAB/SRI ...
Cliff Nearing, It's Lilly's Turn to Restructure
Cliff Nearing, It's Lilly's Turn to Restructure
Pharmion's Euro Bet Pays Off
Pharmion's Euro Bet Pays Off

Topics

Advertisement
UsernamePublicRestriction

Register

PS068798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel